<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958175</url>
  </required_header>
  <id_info>
    <org_study_id>REPEAT</org_study_id>
    <nct_id>NCT03958175</nct_id>
  </id_info>
  <brief_title>The Alouette Test in Parkinson Disease</brief_title>
  <acronym>REPEAT</acronym>
  <official_title>Screening for Reading Difficulties in Parkinson's Disease: An Evaluation of the Alouette Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reading disorders in Parkinson's Disease (PD) are poorly evaluated due to the lack of
      validated tests to screen for them. They are often attributed to hand tremors associated with
      the disease. In this study, the investigating team evaluated the &quot;alouette test&quot; validated
      for dyslexia screening, in PD by comparing the results to healthy patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2015</start_date>
  <completion_date type="Actual">April 1, 2016</completion_date>
  <primary_completion_date type="Actual">April 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score on the Alouette test</measure>
    <time_frame>1 day</time_frame>
    <description>The Alouette test is based on the precision and speed in reading a short text (279 words). The score corresponds to the total number of words correctly read.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Parkinson's Disease</arm_group_label>
    <description>Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without Parkinson's Disease = control group</arm_group_label>
    <description>Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alouette test (reading test)</intervention_name>
    <description>The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.</description>
    <arm_group_label>Patients with Parkinson's Disease</arm_group_label>
    <arm_group_label>Patients without Parkinson's Disease = control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had Parkinson's Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson's Disease

          -  Montreal Cognitive Assessment (MoCA) test &gt; 20

        Exclusion Criteria:

          -  Patient's with supranuclear Palsy

          -  Other neurologic disease

          -  Any ophthalmologic disease

          -  Presence of a nystagmus

          -  Visual acuity &lt; 0.6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibaud Mathis, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

